January 30th, 2012

Additive manufacturing is getting attention for its ability to accelerate the product development process.

The most common types of rapid prototyping methods are additive technologies, meaning that the model is built by adding material layer by layer. By contrast, subtractive prototyping methods create a model by removing material, typically by means of standard machining methods such as milling, grinding and drilling.

A rapid prototype originates with a computer model. Typically, this model is fabricated using computer-aided design (CAD). In some cases, where the final product will be custom-made for the patient, the computer model is created from the patient’s CT scan. A prototyping machine reads the computer data and slices it into different layers. The machine then builds the prototype by adding material layer by layer.

Get a list of the most common rapid prototyping and additive manufacturing method from European Medical Device Technology, where Camilla Andersson also discusses important application areas, including advantages for orthopaedic implants.

 

Maria Fontanazza
No votes yet

Login or register to post comments

January 26th

A bionic arm developed at MIT has an app that gives users more control.

Using the technology with apps also opens up other possibilities Tablets, because they have cameras embedded in them, could enable the bionic arm to be used for remotely based rehab pops up. It also opens up the possiblilty of doing game-based rehab. “This could be used if someone moves x number of degrees, the tablet figures that out and maybe moves like an avatar on a screen, or you build it into a game,” says Stephen Page, PhD, of Ohio State University Medical Center.Traditional rehab is often boring for many patients. “But with game based therapies, patients can lose track of time,” Page says. “And when you have got people with brain injuries, there are sometimes issues with motivation or other factors that may compromise their full participation.” Game-based rehab can become inherently appealing or it can be made more rewarding by adding competitive or social aspect to it."

No votes yet

Login or register to post comments

January 24th

 

In a daily letter from Canaccord Genuity, analysts reiterated a statement made last summer about the end of the glory days in orthopaedics. That is not to say that things won’t get better, but don’t expect to see improvements until the economy as a whole recovers.

Three Manufacturers Who Look Good:
  • China Kangui Holdings. The China-based orthopaedics company continues to grow through its strong product pipeline.
  • NuVasive. The acquisition of Impulse Medical could help strengthen NuVasive’s business strategy.
  • OrthoFix. The company already surpassed analyst revenue expectations for Q4 2011.
Two Takeaways from the Canaccord Analysts:
  • The outlook for industry recovery looks cautious at best. The trends that we saw throughout last year—dropping procedure volumes and pricing pressures—aren’t going anywhere.
  • “Stabilization” is the buzzword in the spine segment. “The ground rules of the spine industry have changed over the past 12-19 months with the government (through FDA and CMS) demanding more data and customers (hospitals and physicians)wanting to pay less for products,” analysts wrote.  

 

Maria Fontanazza
No votes yet

Login or register to post comments

January 19th

 

In 2012, UK-based Stanmore Implants is preparing to take on part of the world (the UK, Europe, and the United States) with a patient-specific knee system that integrates robotics. Although there are technologies that address patient-specific implant
"My general view is that there’s an interest in robotics and computer assistance, and there’s an interest in personalization. We’re offering something that is addressing current strong trends within the orthopaedic field." --Graeme Brookes, Stanmore Implants
creation, the twist on the Savile Row system is that it integrates such an implant with robotics. “Everything from the planning phase through to the implant manufacture and surgical execution is personalized to the patient,” says Graeme Brookes, managing director of computer-assisted surgery and integrated technologies at Stanmore Implants. As a result, accuracy and reproducibility is introduced into the surgical procedure. The implant is a unicondylar knee replacement, which means it preserves more tissue than a total knee replacement.
 
“The robot uses a technology called active constraint. The cutting element of the robot is free to move within a predefined space that is mapped out from the surgical plan. “It’s only when the cutting part of the robot is attempted to be moved into the wrong place that the robot switches on,” says Brookes. “It’s an active constraint mechanism to stop any bone preparation happening in the wrong area.” The technology comes from previously-acquired Acrobot, a spin-out from Imperial College (London). The knee implant was also developed at Imperial College, and the IP was licensed with Stanmore Implants.

Competition

The biggest competition to the Savile Row system is conventional surgery. However, using a robot eliminates multiple instrument trays, which would need to be sterilized and processed. A personalized implant also means less inventory management for hospitals. Although Brookes would not provide a cost position on the implant, he is confident that it will offer hospitals with a value proposition that is equivalent to what they currently have in terms of conventional instruments and off-the-shelf implants.
 
Stanmore Implants is slowly introducing the system to surgeons in a limited amount of centers in the UK. Surgeons have operated on the first group of 20 patients from which the company is gathering data. According to Brookes, the learning curve for surgeons hasn’t been deemed significant.

What's Next 

An obvious evolution would be to apply this technology to other joints (and nonjoint areas), and Stanmore Implants is headed in this direction. “This whole approach in implant development and in using the robot, there’s bandwidth to go vertically and horizontally with it, and that’s what we intend to do,” says Brookes, but he declined to give any clues.
 
For now, the company will be rolling out the product throughout the U.K. the year and has plans to expand into Europe as well. It will also file a 510(k) with FDA this year.
Maria Fontanazza
Your rating: None Average: 4 (1 vote)

Login or register to post comments

January 18th

As metal-on-metal hip implants continue to be scrutinized, here's the latest from Jim Dickinson in MD+DI's Washington Wrap-Up:

A review of clinical trials, observational studies, and registries produced limited evidence on comparative effectiveness of various hip implant bearing combinations, according to an open source British Medical Journal report by researchers from CDRH and universities in the United States and Australia. “Results do not indicate any advantage to metal-on-metal or ceramic-on-ceramic implants compared with traditional metal-on-polyethylene or ceramic-on-polyethylene bearings,” the study concludes....They say they systematically reviewed the evidence as part of that project to determine the short- and long-term outcomes reported by patients undergoing hip replacement and the rates of revision after using implants with various bearings."

 

Maria Fontanazza
No votes yet

Login or register to post comments

January 10th

Medical device packaging company DDL is answering industry demand by adding orthopaedic testing to its services (the company previously conducted testing, but capabilities were limited).

The company now has a biaxial tester, which combines tensile and compression with a torque action. In a company release, DDL notes some tests it offers customers:

  • ASTM F2193, Standard Specifications and Test Methods for Components Used in the Surgical Fixation of the Spinal Skeletal System
  • ASTM F1717, Standard Test Methods for Spinal Implant Constructs in a Vertebrectomy Model
  • ASTM F56, Standard Specification and Test Methods for Metallic Bone Staples
  • ISO 7206-4, Implants for surgery -- Partial and total hip joint prostheses -- Part 4: Determination of endurance properties and performance of stemmed femoral components
  • ISO 14801, Dentistry -- Implants -- Dynamic fatigue test for endosseous dental implants
Maria Fontanazza
No votes yet

Login or register to post comments

January 9th

 

The demand for biomedical textiles continues to grow as device OEMs look for strong yet flexible fabrics to replace
Dean Tulumaris, president and CEO of Biomedical Structures
materials such as metal or plastic, and the movement is increasing competition in this segment of the industry. In a Q&A with the president and CEO of Biomedical Structures (Warwick, RI), Dean Tulumaris talks about the company’s strategy for growth in this expanding market.
 
OrthoTec: What specific areas of development are you seeing within using textiles for devices?
 
Dean Tulumaris: Right now we work with a lot of knit material, woven fabrics, and braids, and we have some unique capabilities with nonwovens. We’ll continue to grow because we’re adding a capability of 36- and 28-gauge knitters for scaffolds and soft tissue. We’re looking at more complex braiding designs, making bifurcated woven stent graft (which is a great new capability), orthopaedic tethers, bifurcated and tapered fabrics, more complex braid assemblies, and inner nonwoven [fabrics] for heart valves. We’re trying to expand our capabilities to support our customers in the orthopaedic and cardiovascular world by making smaller, thinner, and stronger fabrics for their applications.
 
Our goal is to add two or three new capabilities and products to our portfolio every year as we continue to grow.
We’d like to do more subassembly. Our Class 100,000 cleanrooms give us an ability to make and assemble medical products. We’re looking at applications for coatings, adhesives, and hydrogels, as well as packaging and labeling for our customers. Maybe down the road we’ll look at fiber extrusions.
 
As to whether we develop these capabilities in-house or make an acquisition, we’re developing a plan to look at what capabilities and products we want to offer and whether we can build it organically or go outside and make an acquisition to add capabilities.
 
OrthoTec: Are there specific applications in which BMS is focusing to grow its business?
 
Tulumaris:
  • Bifurcated and tapered stent grafts. We don’t play in that arena so we want to work into that.
  • Orthopaedic bifurcated and tapered tethers. 
  • Heart valves, and minimally invasive cardiac solutions. We will continue to make thin nonwovens for those applications.
  • More complex braiding discovery.
  • Finer gauge knitting with scaffolds and meshes.
Biomedical textiles are often used as a replacement for structures in the human body.
OrthoTec: What current challenges does BMS face in the biomedical textiles market?
 
Tulumaris: Right now we’re in a good place; demand is very high.  Our customers want a custom product. For our business, we’re not a commodities company per se. Our strategy is for the niche, highly engineered product to help solve problems in the fabrics industry for our customers. What we’re seeing is that a lot of our customers want the thinner, finer, smaller gauge products, and that’s what we’re working on with them at this point.
 
OrthoTec: What are the BMS goals for 2012?
 
Tulumaris: In 2012 we plan to expand our capabilities with 28 and 36 fine-gauge knitters, laser cutting, and additional value-added capabilities that will simplify our customer's supply chain process. In product development we will continue to expand our bifurcated stent market presence, and expand our braiding capabilities with more complex braids.    
Maria Fontanazza
No votes yet

Login or register to post comments

January 3rd

Over the next five years, the orthopaedics market in Brazil, India, and China will see a boost from medical tourism, better surgeon training, and growing adoption of certain procedures such as cranio maxillofacial fixation.

Some quick stats about the orthopaedic device market, courtesy of GBI Research:
 
  China Brazil India
2010 Value $879 million $575.6 million $385.6 million
2017 Value (expected) $1.5 billion $778.6 million $878.3 million
Strength Major domestic companies that provide strong financial support for R&D. Popular destination for medical tourism. Surgical expenses are 60-80% lower than U.S. costs.
 
 
Maria Fontanazza
No votes yet

Login or register to post comments

December 13th, 2011

A new range of hydroxyapatite (HA) biomaterials have potential new uses in antimicrobial and osteopromotive coatings. They could also be used in the development of bone cements with altered structural features

Calcium phosphate growth after simulated body fluid immersion.

that include toughness, solubility, and porosity. Developed by Ceram, the materials have different biological properties. The company changed the basic chemistry of the material, while keeping its physical structure, by putting different elements into HA.

Ceram has filed a patent on the material and is looking for manufacturing partners. It is also open to forming agreements with research institutions to find new applications for the material.

Related content:

Maria Fontanazza
Your rating: None Average: 3 (1 vote)

Login or register to post comments

December 9th

Exactech has voluntarily extended the terms of its DPA with the U.S. Attorney’s Office for the District of New Jersey for three months. The company had entered into the DPA last December following the 2007 investigation into its consulting agreements with orthopaedic surgeons. The extension, which ends on March 8, 2012, gives the independent monitor more time to examine Exactech's compliance system and how it is working. It's important to note that the U.S. Attorney's Office hasn't stated that Exactech has breached the terms of the DPA. 
 
In September, Wright Medical agreed to a 12-month DPA extension.
 
From the archives:

Maria Fontanazza
No votes yet

Login or register to post comments